# A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

> **NCT05966740** · — · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 6 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05966740
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-19
- **Primary completion:** 2025-04-28
- **Final completion:** 2025-04-28
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Low study enrolment.
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05966740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05966740, "A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05966740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*